Article Text

Download PDFPDF

  1. Jackson Mukonzo1,
  2. Ronald Kuteesa1,
  3. Jasper Ogwal-Okeng1,
  4. Lars L. Gustafsson2,
  5. Joel Owen3,
  6. Eleni Aklillu2
  1. 1Makerere University, Uganda
  2. 2KI, Sweden
  3. 3Union University, United States of America


Background Pharmacogenetics is a major determinant of the EFV–rifampicin interaction during HIV-TB co-treatment. We assessed genetic factors that influence EFV PK, treatment outcomes and provide genotype-based EFV dose recommendations for adult TB-HIV-1 co-infected Ugandans receiving rifampicin based anti-tuberculosis co-treatment.

Methods Steady state plasma EFV concentrations (n=1216) from 158 HIV-TB co-infected patients (76 females) treated with efavirenz/lamivudine/zidovidine and rifampicin-based TB treatment were analysed. Patient genotypes for CYP2B6 (*6 & *11), CYP3A5 (*3,*6 & *7) and ABCB1c.4046A>G, baseline biochemistries and CD4 and viral load change from baseline were determined. A one-compartment population PK model with first-order absorption (NONMEMTM) was used to estimate genotype effects on EFV PK. Population genotype-frequency-based PK simulations predicted AUCs and trough concentrations were compared between the product label / known reference values and different dose simulations.

Results Compared to CYP2B6*1/*1, EFV post-induction CL/F was 2.5 and 1.7 times higher in CYP2B6*6/*6 and CYP2B6*1*/6, respectively. A 23% increase in F1 was observed for the variant ABCB1 c.4046A>G. EFV mean AUC was significantly higher in CYP2B6*6/*6 genotypes compared to CYP2B6*1/*1 (p< 0.0001). Simulated AUCs for a 600 mg EFV dose were 1.2 and 2.4 times greater than the product label mean AUC for the Ugandan population in general and CYP2B6*6/*6 genotypes, respectively. EFV daily doses of 450 mg and 250 mg for the general population and CYP2B6*6/*6 genotypes respectively yielded simulated exposures that were comparable to the product label. Overall, only 8.9% patients had HIV RNA >40 copies/mL after 84 days of treatment.

Conclusions During rifampicin co-treatment, daily doses of 450 mg and 250 mg might meet the EFV dosing needs of HIV-TB infected Ugandans in general and CYP2B6*6 homozygous variants, respectively.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.